For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
HOME > BUSINESS
BUSINESS
- Lonsurf-Bevacizumab Combo Extends Survival in PIII Colorectal Cancer Trial
September 14, 2022
- Otsuka/Lundbeck’s 2-Month Aripiprazole Injectable Accepted for FDA Review
September 14, 2022
- Alnylam Japan Paints Two-Digit Annual Growth Outlook on ATTR Meds and Pipeline Drugs
September 14, 2022
- Lenvima-Keytruda for HCC Misses PIII Primary Goal: Eisai/Merck
September 13, 2022
- Otsuka’s Brexpiprazole Yields Positive Japan PIII Results for Major Depression
September 13, 2022
- Pfizer Seeks Japan Nod for BA.4/5-Adapted COVID-19 Vaccine
September 13, 2022
- Santen CEO Taniuchi Bows Out for Personal Reasons, EVP Ito Takes Helm
September 13, 2022
- Cosentyx 300 mg Pen Approved in Japan: Novartis
September 13, 2022
- Daiichi’s ADC DS-7300 Shows 32% Response in PI/II Solid Tumor Trial
September 13, 2022
- Enhertu Shows Clinically Meaningful Activity in HER2 Mutant NSCLC: Daiichi/AZ
September 13, 2022
- Moderna CEO Visits Fukuoka for Potential Collaboration with Japan
September 13, 2022
- Kowa Files Parmodia Extended-Release Version in Japan
September 13, 2022
- Japan’s First CAD Therapy, Enjaymo, Now Available: Sanofi
September 9, 2022
- Japan Ethical Drug Sales Up 0.8% in July: Crecon
September 9, 2022
- Lagevrio’s Normal Distribution to Start from Sept. 16: MSD
September 9, 2022
- Samsca Generics Get Additional Indication for Heart Failure, AG Too
September 8, 2022
- AnGes Calls off Japan Development of Collategene for Additional Indication
September 8, 2022
- AnGes Jettisons Ancestral COVID-19 Vaccine Program
September 8, 2022
- Promotions via In-Hospital Seminars, Webinars Record Two-Digit Rise YOY in July: Intage
September 7, 2022
- Sysmex Files Gene Profiling Test as CDx for Taiho’s Futibatinib
September 7, 2022
ページ
Earlier this month, the Ministry of Finance (MOF) unveiled a long list of social security proposals towards the FY2025 budgeting,…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…